Journal
BLOOD
Volume 112, Issue 3, Pages 875-885Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2007-12-126938
Keywords
-
Categories
Funding
- NIDDK NIH HHS [R21 DK065169, R21DK065169, R01 DK055463] Funding Source: Medline
Ask authors/readers for more resources
In beta-thalassemia, the mechanism driving ineffective erythropoiesis (1E) is insufficiently understood. We analyzed mice affected by (3-thalassemia and observed, unexpectedly, a relatively small increase in apoptosis of their erythroid cells compared with healthy mice. Therefore, we sought to determine whether IE could also be characterized by limited erythroid cell differentiation. In thalassemic mice, we observed that a greater than normal percentage of erythroid cells was in Sphase, exhibiting an erythroblast-like morphology. Thalassemic cells were associated with expression of cell cycle-promoting genes such as EpoR, Jak2, Cyclin-A, Cdk2, and Ki-67 and the antiapoptotic protein BclXL. The cells also differentiated less than normal erythroid ones in vitro. To investigate whether Jak2 could be responsible for the limited cell differentiation, we administered a Jak2 inhibitor, TG101209, to healthy and thalassemic mice. Exposure to TG101209 dramatically decreased the spleen size but also affected anemia. Although our data do not exclude a role for apoptosis in IE, we propose that expansion of the erythroid pool followed by limited cell differentiation exacerbates IE in thalassemia. In addition, these results suggest that use of Jak2 inhibitors has the potential to profoundly change the management of this disorder.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available